Maria Elisa Mancuso

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to &lt; 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ <scp>PROTECT</scp> Main Study

Bioequivalence of von Willebrand factor-containing concentrates: implications for the choice in patients with von Willebrand disease. A position paper from the Italian Association of Hemophilia Centers

Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to &lt; 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐ <scp>PROTECT</scp> Main Study

The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders

Balancing the benefits and risks of rebalancing coagulation in haemophilia

Implementing Shared Decision-Making in Haemophilia Care: Best Practice Recommendations From a Western European Multi-Stakeholder Delphi Process.

A revised classification of FVIII concentrates: rationale and novel metrics.

Extension Study With rVIII-SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A.

Hemostasis Laboratory Diagnostics in Newborns

Shaping individualized care for women with hemophilia A

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.

Benefits and risks of non-factor therapies: Redefining haemophilia treatment goals in the era of new technologies.

Joint health and pain in the changing hemophilia treatment landscape.

International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal.

Antithrombotic therapy in idiopathic infertility

A post hoc analysis of <scp>PROTECT VIII</scp> kids assessing long‐term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia <scp>A</scp>

Physical Activity, Bleedings and Quality of Life in Subjects with Haemophilia A without Inhibitors-A Multicenter, Observational Italian Study with a Wearable Device.

Future needs for continuing innovation in hemophilia: improving outcomes for individuals of all severities, including women and those in resource-constrained regions.

Better Communication for Better Management of Persons with Hemophilia: Results from a Patients'-Clinicians' Project to Address the New Therapeutic Landscape.

Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life

Real-world clinical and psychosocial outcomes among people with mild or moderate haemophilia A treated on-demand in the Italian CHESS II cohort: a real-world data analysis

Pharmacokinetics of Efmoroctocog alfa by Two-Compartment Model Highlights Hemophilia A Patients with Biphasic Decay, Long Mean Residence Time, and Beta Half-Life.

Synovitis and joint health in patients with haemophilia: Statements from a European e-Delphi consensus study.

Laying the foundations for gene therapy in Italy for patients with haemophilia A: A Delphi consensus study.

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial

Prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures during FVIII inhibitor eradication

Qualification of Hemophilia Treatment Centers to Enable Multi-Center Studies of Gene Expression Signatures in Blood Cells from Pediatric Patients

Befovacimab, an anti‐tissue factor pathway inhibitor antibody: Early termination of the multiple‐dose, dose‐escalating Phase 2 study due to thrombosis

Applicability of the European Society of Cardiology Guidelines on the management of acute coronary syndromes to older people with haemophilia A – A modified Delphi consensus by the ADVANCE Working Group